Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease

rovide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

-- Qualitative diagnosis and referral patterns for the United States

based on thought leader input and guideline recommendations.

-- Quantitative treatment algorithms based on patient-level claims data

Product share (class and specific compound level) within each line

of therapy (1st, 2nd, 3rd line).

-- Practicing physician opinion on why specific drugs are chosen for

certain patient populations.

-- Discussion of key drug combinations (including add versus switch

patterns) by lines of therapy.

-- Progression of therapy from key 1st line products (e.g., initial

treatment with Lipitor to 2nd line, 3rd line; initial treatment with

Zocor to 2nd line, 3rd line).

-- Pathway to key therapies from previous therapies (e.g., how much

Avandamet use is preceded by metformin, Avandia, or both as single


-- Qualitative analysis of 2-year forecast incorporating practicing

physician sentiment towards upcoming launches, changes in

reimbursement, etc.

About Decision Resources

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information,

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
(Date:7/28/2015)... 2015 Seahorse Bioscience, the industry leader ... provider of XF Technology which is increasingly being ... As the links between mitochondrial function and disease ... escalating rapidly.   Recently, 12 peer-reviewed ... Group (NPG) featuring XF Technology, including Nature, Nature ...
(Date:7/28/2015)... 28, 2015 Deerfield Management Company, L.P. today ... L.P., which will invest in groundbreaking advancements in science ... cancer, and orphan diseases. The venture capital fund will ... are developed and improve the way healthcare is delivered ... largest healthcare-focused venture funds in the sector, will donate ...
(Date:7/28/2015)... , July 28, 2015 CSL ... Drug Administration has accepted for review the company,s Biologics ... VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. ... endpoints. Hemophilia A is ... factor VIII; nearly all affected patients are male. People ...
(Date:7/27/2015)... Calif. , July 27, 2015  Amgen (NASDAQ: ... its second quarter financial results on Thursday, July 30, ... The announcement will be followed by a conference call ... in the call from Amgen will be Robert ... other members of Amgen,s senior management team. ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... has launched a pilot program for one Fitchburg neighborhood, ... megabits per secondseveral times higher than the fastest cable ... usage and potential applications of an emerging technology. , ... believe consumers are going to start demanding faster speeds, ...
... Financial Institutions has started distributing ... of incorporation and other papers for ... , ,Under the heading "QuickFile," this ... filing annual reports or forming Wisconsin ...
... made a deal with Georgia-based Cellnet to provide ... overnight event. Certain areas will be initially served before others, ... be approved by the City Council in January and brought ... taken an active role in brokering Cellnets access to city ...
Cached Biology Technology:TDS tries bringing fiber to homes in Fitchburg for faster Internet service 2TDS tries bringing fiber to homes in Fitchburg for faster Internet service 3Madison wireless deal goes forward with Cellnet 2
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... gut bacteria are thought to be involved in colon cancer ... the USA have discovered that a molecule produced by a ... cancer cells. The research, published in the October issue of ... the way gut bacteria can cause colon cancer. There ...
... a dramatic illustration of the potential for microbes to ... of Chicago showed that mice exposed to common stomach ... diabetes. The findings, reported in the journal ... theory that a lack of exposure to parasites, bacteria ...
... Two professors at Cold Spring Harbor Laboratory (CSHL) have ... of proteins that enable genes to express themselves in ... Michael Q. Zhang, Ph.D. and Adrian R. Krainer, ... are exploring a phenomenon that biologists and geneticists call ...
Cached Biology News:Cancer-causing gut bacteria exposed 2'Friendly' bacteria protect against type 1 diabetes, Yale researchers find 2CSHL team traces extensive networks regulating alternative RNA splicing 2CSHL team traces extensive networks regulating alternative RNA splicing 3CSHL team traces extensive networks regulating alternative RNA splicing 4
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Used in May-Grunwald Giemsa stain....
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Biology Products: